Triptolide Amorphous Solid Dispersion for Cancer Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Triptolide, a naturally occurring diterpene with antitumor properties, faces challenges due to poor solubility in water and bioavailability when administered orally or intravenously, limiting its therapeutic effectiveness.
Innovation Solution
A pharmaceutical composition comprising an amorphous solid dispersion of triptolide with specific pharmaceutically acceptable excipients, formulated as oral dosage forms, which maintains a single glass transition temperature and remains amorphous under storage conditions, enhancing solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If triptolide is administered in conventional formulations, then the drug can be delivered to patients, but its poor solubility in water limits its bioavailability and therapeutic effectiveness
Solution Approach 1:
The patent transforms triptolide from its conventional crystalline state to an amorphous state, fundamentally changing its physical parameters. This phase transition eliminates the ordered crystal lattice that causes poor solubility, allowing the drug to dissolve more readily in aqueous environments while maintaining stability through specific excipient formulations
Solution Approach 2:
The patent creates a composite material system by combining amorphous triptolide with specific excipients (such as hydroxypropyl methylcellulose acetate succinate and other polymers). This composite approach leverages the amorphous drug form for improved solubility while using the excipient matrix to provide structural support, control dissolution rate, and prevent recrystallization, thereby achieving enhanced bioavailability
2Reliability
If triptolide is formulated to improve solubility, then bioavailability increases, but maintaining stability under storage conditions becomes challenging
Solution Approach 1:
The patent introduces excipients as intermediary substances that mediate between the amorphous triptolide and the storage environment. These excipients (such as HPMCAS and other polymers) act as protective agents that prevent molecular reorganization and recrystallization of the amorphous drug, thereby maintaining compositional stability while preserving the solubility advantages of the amorphous state
Solution Approach 2:
The patent creates local variations in the formulation matrix by incorporating multiple excipients with different functional properties in specific ratios. This local quality approach ensures that different regions of the formulation provide different functions: some areas prevent recrystallization, others control dissolution, and others provide structural integrity, collectively maintaining stability while enabling high bioavailability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved solubility, bioavailability, and stability, resulting in enhanced pharmacokinetic profiles, increased therapeutic concentrations, and reduced toxicity, effectively treating various cancers including pancreatic cancer, breast cancer, and others.
Implementation Method 1
the composition has a single glass transition temperature
Data Source
AI summary
A pharmaceutical composition containing triptolide or a derivative thereof, as well as methods of using the composition and methods of manufacturing the composition. The composition can be prepared using thermokinetic compounding and can provide improved properties, such as improved bioavailability. The composition can improve the therapeutic treatment of cancers such as pancreatic cancer, breast cancer, bladder cancer, kidney cancer, ovarian cancer, glioblastoma, or melanoma.